瑪麗安Liebert于1980年創立,Mary Ann Liebert inc .是一家獨立出版商的科學、技術、和醫學內容,聞名于世,其先見之明和建立權威的同行評議期刊,書籍,和貿易出版物在尖端領域如生物技術、生物醫學研究、醫學和手術,公共衛生研究和政策、技術、工程、法律、環境研究和政策,和其他專業學科。該公司出版超過90種同行評審期刊，領先的行業雜志，專業通訊，除了社會成員管理和會議。瑪麗·安·利伯特(Mary Ann Liebert)以其遠見卓識的激情和永不停歇的好奇心為動力，通過創建面向市場的專業出版物來識別和培育關鍵主題和前沿領域，這些出版物在推進研究和促進學術界、產業界和政府的合作方面發揮著至關重要的作用。該公司致力于確保最高質量的內容，并有能力長期投資，支持新興市場的出版物直至成熟。該公司的旗艦出版物《基因工程與生物技術新聞》(GEN)于1980年發行，是生物技術領域的第一本同類出版物。今天，GEN是該領域最廣泛閱讀和高度評價的出版物，提供最前沿的新聞和分析技術、應用和趨勢，推動生物技術的未來。自生物技術誕生以來，GEN一直處于該領域的最前沿，保持著無與倫比的完整性、影響力和專業知識，在推動行業生產力和增長方面發揮著關鍵作用。該公司在市場上發表了許多“第一”，包括艾滋病研究和人類逆轉錄病毒，人類基因治療，LGBT健康，以及最近的CRISPR雜志。Mary Ann Liebert, Inc.為作者、圖書館和機構提供了快速和靈活的模型，使發布內容能夠快速傳播和高可視性。該公司的使命是推進研究和開發，促進合作，使最佳治療方案成為可能，并最終改善病人護理。Mary Ann Liebert, Inc.不僅僅是一個出版商，還與企業、教育機構、非營利基金會和其他企業進行有效的合作，包括定制出版物、會議、網絡研討會、協會管理、視頻和時事通訊。這些資源對于公司、協會和機構推進自己的目標發揮著關鍵作用。瀏覽我們的出版物，探索我們已建立的期刊的內容，并了解更多關于我們廣泛的能力。一如既往，瑪麗安歡迎您的反饋和意見，并致力于繼續滿足世界各地學術界、政府和工業界——包括公共和私營部門——的需求。

Founded by Mary Ann Liebert in 1980, Mary Ann Liebert, Inc. is a leading independent publisher of scientific, technical, and medical content, known worldwide for its prescience and establishment of authoritative peer-reviewed journals, books, and trade publications in cutting-edge fields such as biotechnology, biomedical research, medicine and surgery, public health research and policy, technology and engineering, law, environmental research and policy, and other specialized disciplines. The company publishes over 90 peer-reviewed journals, leading trade magazines, and specialized newsletters, in addition to society membership management and conferences.Driven by her visionary passion and ceaseless curiosity, Mary Ann Liebert identifies and nurtures critical topics and cutting-edge fields by creating first-to-market, specialized publications that play a vital role in advancing research and facilitating collaboration in academia, industry, and government. The company is deeply committed to ensuring the highest quality content and is able to invest for the long-term, supporting publications in emerging markets through to maturity.The company’s flagship publication, Genetic Engineering & Biotechnology News (GEN), was launched in 1980, the very first publication of its kind for the field of biotechnology. Today, GEN is the most widely read and highly regarded publication in the field, delivering cutting-edge news and analysis of the technologies, applications, and trends that are driving the future of biotechnology. GEN has been at the forefront of the field since the birth of biotech, maintaining unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry.The company has published many “firsts” in the market, including AIDS Research and Human Retroviruses, Human Gene Therapy, LGBT Health, and, most recently, The CRISPR Journal.Mary Ann Liebert, Inc. provides fast and flexible models for authors, libraries, and institutions that enable rapid dissemination and high visibility of published content. The company’s mission is to advance research and development, foster collaborations that enable best therapeutic options, and, ultimately, to improve patient care.More than just a publisher, Mary Ann Liebert, Inc. collaborates effectively with corporations, educational institutions, nonprofit foundations, and other enterprises in a broad array of extended capabilities that include custom publications, conferences, webinars, association management, videos, and newsletters. These resources play a pivotal role for corporations, associations, and institutions to advance their own goals.Browse our publications, explore the content of our established journals, and learn more about our extensive capabilities. As always, Mary Ann welcomes your feedback and input, and is committed to continuing to meet the needs of the members of academia, government, and industry—in the public and private sectors—around the world.